NCT01747876View on ClinicalTrials.gov

Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 28, 2013

Primary Completion Date

June 29, 2017

Study Completion Date

June 29, 2017

Conditions
Malignant Rhabdoid Tumors (MRT)Neuroblastoma
Interventions
DRUG

LEE011

LEE011 is a small molecule inhibitor of CDK4/6.

Trial Locations (13)

6840

Novartis Investigative Site, Perth

10017

Memorial Sloan Kettering Dept of Onc, New York

30342

Childrens Healthcare of Atlanta Dept of Oncology, Atlanta

50937

Novartis Investigative Site, Cologne

69373

Novartis Investigative Site, Lyon

75231

Novartis Investigative Site, Paris

86156

Novartis Investigative Site, Augsburg

94143

UCSF Medical Center Dept of Pediatic Oncology, San Francisco

94805

Novartis Investigative Site, Villejuif

02215

Dana Farber Cancer Institute SC-7, Boston

45229-3039

Cincinnati Children's Hospital Medical Center Dept of Oncology, Cincinnati

38105-2794

St Jude s Childrens Research Hospital Dept of Oncology, Memphis

SM2 5PT

Novartis Investigative Site, Sutton

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY